- | Heat Biologics
Immuno-oncology Enterprises Entering COVID
The era of COVID-19 has brought on some exciting developments with the types of biopharmaceutical enterprises that are developing therapies and vaccines to treat the disease. Specifically, immuno-oncology enterprises are delving into the area, as their immunotherapies can also coincide with mechanisms of action that can also treat COVID. In this interview, Lori McDermott, VP, Clinical Development & Regulatory Affairs at Heat Biologics, will discuss their approaches towards developing a COVID therapy.
- | DURECT
Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study
Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.
- | Vaccinex
Pepinemab Clinical Trial Ongoing; Top-line Results Coming Later this Year
Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in all 265 patients enrolled in cohort B, the company announced.
- | Recce Pharmaceuticals
Data recommend RECCE 327
Australian drug developer Recce Pharmaceuticals has announced new data showing significant in-vivo antibacterial activity in mice treated with its lead compound RECCE 327 against Neisseria gonorrhoeae, the second most common sexually transmitted infection (STI). RECCE 327 is among a new class of synthetic antibiotics with broad-spectrum activity developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their drug-resistant forms.
Announcing the 2020 Bulldog PR Award Winners—congrats, top dogs!
Best Use of Social Media
– Bronze: Using the Power of Social Media to Engage with Target Audiences in a Crowded Disease Space by LifeSci Communications
Best Use of Social Media
- Bronze: Using the Power of Social Media to Engage with Target Audiences in a Crowded Disease Space by LifeSci Communications
- | Immuneering
Episode 5: Finding Funding In Volatile Times With Ben Zeskind
Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the development of its pipeline at the outset of the COVID-19 pandemic. Along the way, it bootstrapped its way from bioinformatics company to fledgling biopharma. On this episode of The Business Of Biotech, Zeskind shares his experience-based wisdom on finding funding in volatile times.
- | Aerami Therapeutics
Pharmafocus June 2020
“Seeing a group of people become a team and achieving more than they thought was possible inspires me” – Anne Whitaker, CEO, Aerami Therapeutics
- | NantKwest
Operation Warp Speed selects billionaire scientist’s COVID-19 vaccine for monkey tests
The race for a COVID-19 vaccine has a dark horse entrant. Billionaire scientist and businessman Patrick Soon-Shiong announced in a 27 May investor call and press release that an experimental vaccine being developed by two of his companies is on the short list of 14 candidates being evaluated by Operation Warp Speed, the Trump administration’s push to deliver 300 million doses of safe and effective COVID-19 vaccines by January 2021.
